Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead
- Everardo González-González,
- Mario Moisés Alvarez(corresponding author),
- Alan Roberto Márquez-Ipiña,
- Grissel Trujillo-de Santiago,
- ,
- Nasim Annabi
- Instituto Tecnologico de Estudios Superiores de Monterrey,
- Harvard University,
- Massachusetts Institute of Technology,
- Centro de Biotecnología-FEMSA,
- Northeastern University,
- Konkuk University
Sustainable Development Goals
SDG 3 Good Health and Well
Publication metrics
Metrics
Abstract
The 2014 Ebola outbreak, the largest recorded, took us largely unprepared, with no available vaccine or specific treatment. In this context, the World Health Organization declared that the humanitarian use of experimental therapies against Ebola Virus (EBOV) is ethical. In particular, an experimental treatment consisting of a cocktail of three monoclonal antibodies (mAbs) produced in tobacco plants and specifically directed to the EBOV glycoprotein (GP) was tested in humans, apparently with good results. Several mAbs with high affinity to the GP have been described. This review discusses our current knowledge on this topic. Particular emphasis is devoted to those mAbs that have been assayed in animal models or humans as possible therapies against Ebola. Engineering aspects and challenges for the production of anti-Ebola mAbs are also briefly discussed; current platforms for the design and production of full-length mAbs are cumbersome and costly.
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 53-68 (16 pages)Journal (Volume, Issue Number)
Critical Reviews in Biotechnology (Volume 37, Issue 1)Publication milestones
- Published - 02/01/2017
Publication status
ISSN
0738-8551Publication IDs
- Scopus: 84948160387
- PubMed: 26611830